Cerus Q3 2026 Net Loss Widens to $550,000

PUBT · 22h ago
Cerus Q3 2026 Net Loss Widens to $550,000
  • Cerus’ third-quarter 2026 net loss attributable to the company widened year-over-year to $550,000.
  • Total revenue rose 6% year-over-year to $64 million, while product revenue increased 10% to $57.71 million.
  • Third-quarter operating cash flow climbed 58% year-over-year to $3 million.
  • Positive topline results from the Phase 3 RedeS trial marked a milestone for the INTERCEPT Blood System for red blood cells.
  • Full-year 2026 product revenue guidance remained $229 million to $231 million, including $23 million to $25 million from IFC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021605BIZWIRE_USPR_____20261102_BW374071) on November 02, 2026, and is solely responsible for the information contained therein.